Trial Profile
An Adaptive Dose-Ranging, Multi-Center, Single-Blind, Double-Dummy, Active-Controlled Trial to Determine the Target Dose of Canakinumab (ACZ885) in the Treatment of Acute Flares in Gout Patients Who Are Refractory or Contraindicated to NSAIDs and/or Colchicine.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary) ; Triamcinolone
- Indications Gout; Gouty arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 23 Jun 2012 Planned patient number of extension trial (EudraCT2009-012316-40) changed from 300 to 320.
- 23 Jun 2012 Planned patient number of extension trial (EudraCT2009-012316-40) changed from 300 to 320.
- 25 Mar 2011 Acute flare and improves health-related quality-of-life results published in the Arthritis Research and Therapy.